Skip to main content
. 2018 Jul 10;4:65. doi: 10.1038/s41420-018-0067-0

Fig. 2. Drug screening identifies Oxa12 as necroptosis inhibitor in BV2 microglia cells.

Fig. 2

a Schematic overview of the drug screening workflow. b Normalized necroptosis inhibition values depicted as percentage of control (DMSO) for compounds (30 µM) tested on BV2 cells exposed to 25 µM zVAD-fmk for 24 h. Results are presented as the mean value ± SEM of at least three independent experiments performed in duplicates. c Oxa12 chemical structure. d BV2 cells were incubated with Oxa12 (0.1–50 µM) plus zVAD-fmk (25 µM) for 24 h. e BV2 cells were incubated with Oxa12 (1–150 µM) for 24 h. Cell viability was determined by the MTS metabolism assay. The results are presented as the mean value ± SEM of three independent experiments performed in duplicates and normalized to vehicle control (DMSO)